228 related articles for article (PubMed ID: 27131284)
1. Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran.
Ellinghaus P; Perzborn E; Hauenschild P; Gerdes C; Heitmeier S; Visser M; Summer H; Laux V
Thromb Res; 2016 Jun; 142():44-51. PubMed ID: 27131284
[TBL] [Abstract][Full Text] [Related]
2. Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves.
Wypasek E; Natorska J; Mazur P; Kopytek M; Gawęda B; Kapusta P; Madeja J; Iwaniec T; Kapelak B; Undas A
Vascul Pharmacol; 2020 Jul; 130():106679. PubMed ID: 32387621
[TBL] [Abstract][Full Text] [Related]
3. Expression of anti and pro-inflammatory genes in human endothelial cells activated by 25-hydroxycholesterol: A comparison of rivaroxaban and dabigatran.
Gorzelak-Pabiś P; Pawlos A; Broncel M; Wojdan K; Woźniak E
Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):805-812. PubMed ID: 35577580
[TBL] [Abstract][Full Text] [Related]
4. An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban.
Wan H; Yang Y; Zhu J; Wu S; Zhou Z; Huang B; Wang J; Shao X; Zhang H
Blood Coagul Fibrinolysis; 2016 Dec; 27(8):882-885. PubMed ID: 26757012
[TBL] [Abstract][Full Text] [Related]
5. The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Buijs JT; Laghmani EH; van den Akker RFP; Tieken C; Vletter EM; van der Molen KM; Crooijmans JJ; Kroone C; Le Dévédec SE; van der Pluijm G; Versteeg HH
J Thromb Haemost; 2019 Jun; 17(6):951-963. PubMed ID: 30929299
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Strandberg K
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512144
[No Abstract] [Full Text] [Related]
7. Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants.
Papadaki S; Sidiropoulou S; Moschonas IC; Tselepis AD
Platelets; 2021 Aug; 32(6):807-814. PubMed ID: 32762584
[TBL] [Abstract][Full Text] [Related]
8. Demeanor of rivaroxaban in activated/inactivated FXa.
Seki K; Mizuno Y; Sakashita T; Nakano S; Tanno J; Okazaki Y; Muramatsu T; Nishimura S; Senbonmatsu T
J Pharmacol Sci; 2017 Mar; 133(3):156-161. PubMed ID: 28314697
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Wong PC; White A; Luettgen J
Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
[TBL] [Abstract][Full Text] [Related]
10. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
11. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
[TBL] [Abstract][Full Text] [Related]
12. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Perzborn E; Heitmeier S; Buetehorn U; Laux V
J Thromb Haemost; 2014 Jul; 12(7):1054-65. PubMed ID: 24766850
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation.
Jaffer IH; Fredenburgh JC; Stafford A; Whitlock RP; Weitz JI
Ann Thorac Surg; 2020 Aug; 110(2):582-590. PubMed ID: 31877292
[TBL] [Abstract][Full Text] [Related]
14. The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.
Gessoni G; Valverde S; Gessoni F; Valle R
Blood Transfus; 2015 Oct; 13(4):666-8. PubMed ID: 25761318
[No Abstract] [Full Text] [Related]
15. Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
Aungraheeta R; FitzGibbon L; Reilly-Stitt C; Mumford AD
Int J Lab Hematol; 2020 Apr; 42(2):126-133. PubMed ID: 31756037
[TBL] [Abstract][Full Text] [Related]
16. Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice.
Rahadian A; Fukuda D; Salim HM; Yagi S; Kusunose K; Yamada H; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2020 Jan; 124():106632. PubMed ID: 31759113
[TBL] [Abstract][Full Text] [Related]
17. Effect of rivaroxaban and dabigatran on platelet functions: in vitro study.
Jourdi G; Bachelot-Loza C; Mazoyer E; Poirault-Chassac S; Duchemin J; Fontenay M; Gaussem P
Thromb Res; 2019 Nov; 183():159-162. PubMed ID: 31678711
[TBL] [Abstract][Full Text] [Related]
18. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
Olivier CB; Weik P; Meyer M; Weber S; Anto-Michel N; Diehl P; Zhou Q; Geisen U; Bode C; Moser M
Thromb Res; 2016 Feb; 138():63-68. PubMed ID: 26610745
[TBL] [Abstract][Full Text] [Related]
19. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.
Sparkenbaugh EM; Chantrathammachart P; Mickelson J; van Ryn J; Hebbel RP; Monroe DM; Mackman N; Key NS; Pawlinski R
Blood; 2014 Mar; 123(11):1747-56. PubMed ID: 24449213
[TBL] [Abstract][Full Text] [Related]
20. [Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy].
Szegedi N; Gellér L; Tahin T; Merkely B; Széplaki G
Orv Hetil; 2016 Jan; 157(4):154-6. PubMed ID: 26772828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
